The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | The significance of anemia in MDS & MPNs and the need to develop effective therapies
Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, shares insights into the significance of anemia in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), highlighting its association with poor prognosis due to cardiovascular complications, iron overload, and increased disease severity. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
